Chardan Capital Issues Optimistic Forecast for FDMT Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Research analysts at Chardan Capital raised their FY2025 EPS estimates for 4D Molecular Therapeutics in a report released on Tuesday, November 11th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of ($2.14) for the year, up from their previous forecast of ($3.52). Chardan Capital has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

FDMT has been the subject of several other reports. Royal Bank Of Canada upped their price objective on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Barclays reduced their price objective on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday. Roth Capital dropped their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Finally, Leerink Partners reissued an “outperform” rating and issued a $17.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.70.

4D Molecular Therapeutics Trading Down 6.3%

Shares of FDMT stock opened at $10.28 on Friday. The company has a market cap of $587.30 million, a P/E ratio of -2.74 and a beta of 2.96. The firm has a fifty day moving average price of $9.25 and a 200 day moving average price of $6.21. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $41,000. Proficio Capital Partners LLC lifted its stake in shares of 4D Molecular Therapeutics by 26.0% in the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock worth $75,000 after acquiring an additional 5,195 shares during the period. Federated Hermes Inc. boosted its holdings in shares of 4D Molecular Therapeutics by 33,131.8% in the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock valued at $4,038,000 after acquiring an additional 1,246,419 shares in the last quarter. Privium Fund Management B.V. increased its stake in shares of 4D Molecular Therapeutics by 8.3% during the first quarter. Privium Fund Management B.V. now owns 131,000 shares of the company’s stock worth $423,000 after acquiring an additional 10,000 shares during the period. Finally, Invesco Ltd. raised its holdings in 4D Molecular Therapeutics by 318.3% during the first quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock worth $380,000 after purchasing an additional 89,611 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Insider Transactions at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 2,678 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the transaction, the insider owned 3,594 shares in the company, valued at $43,128. The trade was a 42.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 9,128 shares of company stock valued at $92,100. Insiders own 9.60% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.